Non-Regulatory

April 30, 2020

Affibody Announces Option Exercise by Daewoong

Solna, Sweden, April 30, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced that its partner Daewoong, a South Korea-based...

Read more

Non-Regulatory

February 21, 2020

Year End Report 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today...

Read more

Non-Regulatory

February 3, 2020

Notice of EGM (Kallelse till extra bolagsstämma)

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 17 februari 2020 kl 14.00 i bolagets lokaler, Scheeles väg 2, Solna.

Read more

Non-Regulatory

November 15, 2019

Interim Report – January to September 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued...

Read more

Non-Regulatory

September 23, 2019

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi- and multi-specific drug projects, today announced its relocation to the...

Read more

Non-Regulatory

September 20, 2019

Affibody and GE Healthcare to Collaborate on Development of Affibody® PET Imaging Tracers

Solna, Sweden, September 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced a strategic collaboration with GE Healthcare to...

Read more

Non-Regulatory

August 23, 2019

Interim Report – January to June 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its...

Read more

Non-Regulatory

July 16, 2019

Affibody Announces Interim Analysis in Phase 2 Psoriasis Trial of ABY-035

Solna, Sweden, July 16, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of the planned 12 week...

Read more

Non-Regulatory

June 17, 2019

Affibody to Present at Affinity 2019

Solna, Sweden, June 17, 2019. Affibody AB (“Affibody”), a clinical stage biotech company, today announced that Prof. Fredrik Frejd, CSO, will present at the Affinity 2019 conference in June.

Read more